Probi AB and Wageningen University enter long-term research collaboration

Probi AB today announces a four-year collaborative research agreement with
Professor Michiel Kleerebezem at the Host Microbe Interactomics Group at
Wageningen University. The aim of the collaboration is to clarify mechanisms of
action for anti-inflammatory activity of probiotic bacteria in order to enable a
continued development of novel effective probiotic products.

Probi develops and markets well-documented probiotics for supplements and
functional foods predominantly targeting immune function and gastrointestinal
health. Probi´s ambition is to acquire an in-depth understanding of mechanisms
of action of beneficial commensal bacteria, in order to continue to develop
probiotic strains within new areas of benefit for the consumer.

The Host Microbe Interactomics Group at the Wageningen University combines
expertise in cell biology, immunology, microbiology and functional genomics to
increase the understanding of molecular interactions occurring in the cross-talk
between microbes and their hosts. Its research ranges from work on the molecular
mechanisms of diseases caused by pathogenic bacteria to the interactions between
beneficial bacteria and their hosts.

Together Probi and the Host Microbe Interactomics Group at Wageningen University
now want to study the physiological relevance and health-beneficial effects of
various probiotic strains both in vitro and in vivo. The collaboration covers a
four-year PhD project plan, and aims to provide proof of concept for the
physiological relevance of new probiotic strains in the attenuation of
intestinal inflammation, which plays a pivotal role in various pathologic
conditions.

“Probi is a company that understands how important it is to define and clarify
the probiotic products’ mechanisms of action. That view was the main reason that
we started to discuss a collaboration”, says Michiel Kleerebezem, professor at
Wageningen University & Research Centre in the Netherlands.

“We see this collaboration as an important step in our future product
development, and are pleased to announce the collaboration with Professor
Kleerebezem and his group. I personally believe that this project will lead to a
much better understanding of anti-inflammatory probiotics and provide an
opportunity for Probi to develop novel products in new and interesting fields”
says Peter Nählstedt, CEO of Probi AB.

The information is such that Probi AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.

FOR FURTHER INFORMATION, CONTACT:

Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e
-mail: peter.nahlstedt@probi.se

Gun-Britt Fransson, Vice President Research & Development, Probi, tel +46 46 286
89 74 or mobile +46 705 95 73 27, e-mail: gun-britt.fransson@probi.se

ABOUT PROBI

Probi AB is a Swedish publicly traded bioengineering company that develops
effective and well-documented probiotics. Through its world-leading research,
Probi has created a strong product portfolio in the gastrointestinal health and
immune system niches. Probi’s products are available to consumers in more than
30 countries worldwide. Probi’s customers are leading food, health-product and
pharmaceutical companies in the Functional Food and Consumer Healthcare
segments. In 2014, Probi had sales of MSEK 135. The Probi share is listed on
NASDAQ OMX Stockholm, Small Cap. Probi has about 3,000 shareholders. Read more
at www.probi.se